

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS
- *LINES*

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

What is claimed is:

1. An immunopolypeptide that binds to human glucose-6-phosphate isomerase with a dissociation constant of no more than about 10^{-7} .

5

2. An isolated immunoglobulin antibody that specifically binds to human glucose-6-phosphate isomerase

10 3. An immunopolypeptide comprising at least one CDR sequence selected from the group consisting of SEQ ID NO's: 15-56 or a significant homolog thereof.

4. An immunopolypeptide according to claim 3 having a triplet of CDR sequences.

15 5. An immunopolypeptide according to claim 4 wherein each CDR of the triplet is separated from other CDR's by a spacer amino acid sequence.

6. An immunopolypeptide according to claim 5 wherein the spacer amino acid sequence is a framework region sequence having an amino acid sequence selected from the group consisting of SEQ ID NO's:57-108 or a significant homolog thereof.

20

7. An immunopolypeptide according to claim 6 wherein the CDR's of the triplet are selected from either a light chain group or a heavy chain group.

25 8. An immunopolypeptide according to claim 7 wherein the CDR's are matched according to their Fab source.

9. An immunopolypeptide according to claim 8 wherein the framework region sequence is matched to the Fab source of the CDR triplet.

10. An immunopeptide according to claim 9 wherein the amino acid sequence is a V_L or V_H fragment of the Fab source of the matched CDR triplet and framework regions.

5 11. An immunopeptide having an amino acid sequence substantially homologous to a sequence selected from the group consisting of SEQ ID NO's: 1-14.

12. An immunopeptide according to claim 11 which is a combination of V_L and V_H .

10

13. An immunopeptide according to claim 11 which further includes at least one constant consensus region.

15

14. An immunopeptide according to claim 13 which is a combination of a light and heavy chain fragment.

15. An immunopeptide according to claim 14 which is an Fab, Fab', F(ab')₂, Fd, scFv or Fv fragment.

20

16. An anti-GPI monoclonal antibody having CDR and framework segments with significant homology to the amino acid sequences set forth in SEQ ID NO's: 15-108.

17. A immunopeptide encoded in a bacteriophage that is deposited with the ATCC.

25

18. An immunopeptide Fab fragment having a light variable chain amino acid sequence selected from the group consisting of SEQ ID NO's: 1-7 and a heavy variable amino acid sequence selected from the group consisting of SEQ ID NO's: 8-14.

30

19. An immunopeptide Fab fragment having its CDR amino acid sequences of its light chain selected from the group consisting of SEQ ID NO's: 36-56 and its CDR

amino acid sequence of its heavy chain sequence selected from the group consisting of SEQ ID NO's: 15-35.

20. An anti-idiotypic antibody that specifically binds with anti-glucose-6-phosphate 5 isomerase antibody.

21. An anti-idiotypic antibody according to claim 20 which binds with a hypervariable region segment of anti-glucose-6-phosphate antibody

10 22. A second immunopeptide that specifically binds with anti-6-phosphate isomerase antibody.

23. A second immunopeptide according to claim 22 that specifically binds with a variable region segment of anti-6-phosphate isomerase.

15 24. An antisense oligonucleotide that specifically hybridizes with a polynucleotide encoding anti-glucose-6-phosphate isomerase antibody or encoding glucose-6-phosphate isomerase.

20 25. An antisense oligonucleotide according to claim 24 having a non-natural modification.

26. An antisense oligonucleotide according to claim 25 having at least one thiophosphate group, a base alkylation group or a non-natural base group.

25 27. A conjugate of human glucose-6-phosphate isomerase covalently bonded to, complexed with, or associated with, a cytotoxic agent.

28. A composition comprising immobilized human glucose-6-phosphate isomerase.

30 29. A nucleotide sequence encoding an immunopeptide according to claim 1.

30. A nucleotide sequence having a sequence selected from the group consisting of SEQ ID NOs: 109-122.

31. A nucleotide sequence encoding an anti-glucose-6-phosphate isomerase antibody.

5

32. A nucleotide sequence encoding a humanized chimeric monoclonal antibody according to claim 20.

10 33. A pharmaceutical composition comprising an immunopeptide of claim 1 and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising an anti-idiotypic antibody according to claim 20 and a pharmaceutically acceptable carrier.

15 35. A pharmaceutical composition comprising a second immunopeptide according to claim 22 and a pharmaceutically acceptable carrier.

36. A pharmaceutical composition comprising an antisense oligonucleotide according to claim 24 and a pharmaceutically acceptable carrier.

20

37. A pharmaceutical composition comprising a conjugate according to claim 27 and a pharmaceutically acceptable carrier.

25 38. A method for diagnosis of autoimmune disease comprising determining the presence of an immune complex formed by combining the blood sera of a patient with human glucose-6-phosphate isomerase.

30 39. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of an immunopeptide according to claim 1.

40. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of a humanized chimeric monoclonal antibody according to claim 20.

5 41. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of a second immunopeptide according to claim 22.

10 42. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of a conjugate according to claim 27.

15 43. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of an antisense oligonucleotide according to claim 24.

44. A method for treatment of a patient having autoimmune disease comprising filtering the patient's blood extracorporeally through a filter system containing immobilized human glucose-6-phosphate isomerase.

20 45. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective desensitizing amount of human glucose-6-phosphate isomerase.

25 46. An antisense oligonucleotide according to claim 24 which hybridizes with the nucleotide sequence encoding the antibody.